IE51342B1 - Substituted pyrazinyl-1,2,4-oxadiazol-5-ones,a process for preparing same and a pharmaceutical composition containing same - Google Patents
Substituted pyrazinyl-1,2,4-oxadiazol-5-ones,a process for preparing same and a pharmaceutical composition containing sameInfo
- Publication number
- IE51342B1 IE51342B1 IE1431/81A IE143181A IE51342B1 IE 51342 B1 IE51342 B1 IE 51342B1 IE 1431/81 A IE1431/81 A IE 1431/81A IE 143181 A IE143181 A IE 143181A IE 51342 B1 IE51342 B1 IE 51342B1
- Authority
- IE
- Ireland
- Prior art keywords
- compound
- pharmaceutical composition
- hydrogen
- hypertension
- formula
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 206010020772 Hypertension Diseases 0.000 claims abstract description 7
- 206010030113 Oedema Diseases 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 229960002003 hydrochlorothiazide Drugs 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- ALYSDVMPAXWPNM-UHFFFAOYSA-N 3-pyrazin-2-yl-2h-1,2,4-oxadiazol-5-one Chemical class N1OC(=O)N=C1C1=CN=CC=N1 ALYSDVMPAXWPNM-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- KSEHSAXZBNRCCY-UHFFFAOYSA-N 3-chloropyrazine-2,6-diamine Chemical compound NC1=CN=C(Cl)C(N)=N1 KSEHSAXZBNRCCY-UHFFFAOYSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- -1 6-chloro-N-(cyanoaminoiminomethyl)pyrazinecarboxamide Chemical compound 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WWCISNWFARWAER-UHFFFAOYSA-N n-[(2-cyanohydrazinyl)methylidene]pyrazine-2-carboxamide Chemical class N#CNNC=NC(=O)C1=CN=CC=N1 WWCISNWFARWAER-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/163,614 US4309430A (en) | 1980-06-27 | 1980-06-27 | Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE811431L IE811431L (en) | 1981-12-27 |
| IE51342B1 true IE51342B1 (en) | 1986-12-10 |
Family
ID=22590790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1431/81A IE51342B1 (en) | 1980-06-27 | 1981-06-26 | Substituted pyrazinyl-1,2,4-oxadiazol-5-ones,a process for preparing same and a pharmaceutical composition containing same |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4309430A (enExample) |
| EP (1) | EP0043123B1 (enExample) |
| JP (1) | JPS5756480A (enExample) |
| AT (1) | ATE7697T1 (enExample) |
| DE (1) | DE3163867D1 (enExample) |
| DK (1) | DK283881A (enExample) |
| ES (1) | ES8300758A1 (enExample) |
| GR (1) | GR74609B (enExample) |
| IE (1) | IE51342B1 (enExample) |
| PT (1) | PT73259B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5066662A (en) * | 1990-05-21 | 1991-11-19 | Warner-Lambert Company | Substituted oxazolidin-2-ones and 1,2,4-oxadiazolin-5-ones and derivatives thereof acting at muscarinic receptors |
| AU2009313198B2 (en) | 2008-11-10 | 2016-03-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| MX2011006503A (es) | 2008-12-19 | 2011-09-06 | Vertex Pharma | Derivados de pirazina utiles como inhibidores de la cinasa de atr. |
| WO2011143423A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2011143399A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2011143419A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
| EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| CN102947272A (zh) | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的2-氨基吡啶衍生物 |
| AU2011253025A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013529643A (ja) | 2010-06-23 | 2013-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用なピロロピラジン誘導体 |
| CN103562204A (zh) | 2011-04-05 | 2014-02-05 | 沃泰克斯药物股份有限公司 | 可用作tra激酶的抑制剂的氨基吡嗪化合物 |
| WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2012178124A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| SG10201602515QA (en) | 2011-09-30 | 2016-05-30 | Vertex Pharma | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| ES2751741T3 (es) | 2011-09-30 | 2020-04-01 | Vertex Pharma | Procedimiento para fabricar compuestos útiles como inhibidores de la quinasa ATR |
| US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2014528419A (ja) | 2011-09-30 | 2014-10-27 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用なピラジン化合物 |
| WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP3311816A1 (en) | 2012-04-05 | 2018-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase for the treatment of cancer |
| WO2014055756A1 (en) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
| WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| HUE052808T2 (hu) | 2012-12-07 | 2021-05-28 | Vertex Pharma | Pirazolo[1,5-A]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| BR112016012734B1 (pt) | 2013-12-06 | 2022-09-13 | Vertex Pharmaceuticals Incorporated | Composto de 2-amino-6-flúor-n-[5-flúor-piridin-3-il]pirazol[1,5-a]pirimidin-3-carboxamida, formas sólidas, composição, seu uso e processo para a preparação do referido composto |
| RU2719583C2 (ru) | 2014-06-05 | 2020-04-21 | Вертекс Фармасьютикалз Инкорпорейтед | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы |
| RS59054B1 (sr) | 2014-06-17 | 2019-08-30 | Vertex Pharma | Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora |
| MX395066B (es) | 2015-09-30 | 2025-03-24 | Vertex Pharma | Método para tratar cáncer usando una combinación de agentes que dañan el adn e inhibidores de proteína relacionada con ataxia telangiectasia y rad3 (atr). |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3515723A (en) * | 1967-11-14 | 1970-06-02 | Merck & Co Inc | 2 - (5 - amino - 1h - 1,2,4 - triazol - 3 - yl)- 3-aminopyrazines and processes for their preparation |
| US3770739A (en) * | 1972-09-11 | 1973-11-06 | American Cyanamid Co | Cyclorpropyl-1,2,4-oxadiazolylpyrazines |
-
1980
- 1980-06-27 US US06/163,614 patent/US4309430A/en not_active Expired - Lifetime
-
1981
- 1981-06-22 GR GR65307A patent/GR74609B/el unknown
- 1981-06-23 ES ES503308A patent/ES8300758A1/es not_active Expired
- 1981-06-25 PT PT73259A patent/PT73259B/pt unknown
- 1981-06-26 EP EP81104974A patent/EP0043123B1/en not_active Expired
- 1981-06-26 IE IE1431/81A patent/IE51342B1/en unknown
- 1981-06-26 JP JP56098426A patent/JPS5756480A/ja active Pending
- 1981-06-26 DK DK283881A patent/DK283881A/da not_active Application Discontinuation
- 1981-06-26 AT AT81104974T patent/ATE7697T1/de active
- 1981-06-26 DE DE8181104974T patent/DE3163867D1/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IE811431L (en) | 1981-12-27 |
| JPS5756480A (en) | 1982-04-05 |
| ES503308A0 (es) | 1982-11-01 |
| EP0043123B1 (en) | 1984-05-30 |
| ATE7697T1 (de) | 1984-06-15 |
| GR74609B (enExample) | 1984-06-29 |
| PT73259B (en) | 1983-06-28 |
| DE3163867D1 (en) | 1984-07-05 |
| PT73259A (en) | 1981-07-01 |
| DK283881A (da) | 1981-12-28 |
| ES8300758A1 (es) | 1982-11-01 |
| EP0043123A1 (en) | 1982-01-06 |
| US4309430A (en) | 1982-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4309430A (en) | Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same | |
| US3573306A (en) | Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides | |
| US4460607A (en) | Lipid absorption-inhibiting agents and their use | |
| JPS6156227B2 (enExample) | ||
| US4309540A (en) | Substituted pyrazinyl-1,2,4-oxadiazoles | |
| JPS5989671A (ja) | ２，５−ピペラジンジオン誘導体 | |
| US4454132A (en) | Pharmaceutical compositions of novel substituted pyrazinyl-1,2,4-oxadiazoles useful in the treatment of edema and hypertension | |
| EP0017153B1 (en) | Novel pyrazinecarboxamides, processes for preparing and pharmaceutical compositions containing the same | |
| US4362724A (en) | Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic | |
| US3923994A (en) | Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity | |
| US3586688A (en) | Certain aminopyridinecarbonyl guanidines | |
| US4360521A (en) | 7[3,6-Dihydro-1(2H)-pyridyl]-2-oxo-2H-[1,2,4]oxadiazolo[2,3-c]pyrimidine-5-carbamate compounds | |
| US3021325A (en) | Carbamyl substituted 2, 3, 4, 5-tetrahydrobenzodiazepine compounds | |
| GB1580588A (en) | -aryl- , -bis( -(disubstituted amino)-alkyl)-acetamides and related compounds | |
| US4328235A (en) | Suppressing pain with benzothiazol-2(3H)-ones | |
| US2928768A (en) | Use of substituted amino-formoguanamines in diuretic therapy | |
| NL8202227A (nl) | 4-amino.benzylaminederivaten en werkwijzen voor hun bereiding en hun toepassing als farmaceutica. | |
| DE2613328C3 (de) | l-Methyl-2-(m-trifluormethyl-phenyl)äthylamid der p-Pentylamino-phenoxyessigsäure, ein Verfahren zu dessen Herstellung sowie Arzneimittel | |
| US3968217A (en) | 5-(3-)SUBSTITUTED-10,11-DIHYDRO-5H-dibenz[b,f]azepines | |
| JPH0146511B2 (enExample) | ||
| US3818095A (en) | Compositions of 1,2-dilower alkyl-3(and/or4)-aryl-3-pyrazolines and salts thereof and method of lowering blood sugar levels with same | |
| US3969532A (en) | 1-Aryl-3-(2-hydroxyethyl) thioureas for treating depression | |
| CA2315835C (en) | New crystalline form of 1-methyl-5-p-toluoylpyrrole-2-acetamidoacetic acid guaiacyl ester | |
| US3655894A (en) | Compositions for inhibiting gastric acid secretion | |
| JPS61158970A (ja) | ピラジンジアゾヒドロキシド化合物 |